Consolidated Q2 FY27 vs Q2 FY26: revenue Rs 874 Cr vs Rs 731 Cr; PAT up 27.5%
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Smallcap 250 and 4.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended September 30, 2026, revenue was Rs 874 crore versus Rs 731 crore in Q2 FY26, up 19.6%, while profit after tax rose 27.5% to Rs 194 crore from Rs 152 crore. EBITDA rose 25.1% to Rs 280 crore, with margin up to 32.1% from 30.7%. For H1 FY27, consolidated revenue was Rs 1,672 crore and profit after tax Rs 364 crore. A 50% interim dividend of Rs 5 per share was declared.
Stronger profit and margin growth plus a 50% interim dividend may support shareholder sentiment, though quarterly revenue growth was just below 20%.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.